Arcutis Biotherapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

ARQT$27.39+4.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except per share data)

	Year Ended December 31,
	2025	2024	2023
Revenues:
Product revenue, net	$372,072	$166,542	$29,186
Other revenue	4,000	30,000	30,420
Total revenues	376,072	196,542	59,606
Operating expenses:
Cost of sales	36,695	19,128	4,987
Research and development	77,051	76,420	110,575
Selling, general and administrative	274,553	229,391	185,145
Total operating expenses	388,299	324,939	300,707
Loss from operations	(12,227)	(128,397)	(241,101)
Other income (expense):
Interest income	8,897	16,126	12,517
Interest expense	(12,083)	(27,168)	(29,712)
Other income (expense), net	443	47	(731)
Loss before income taxes	(14,970)	(139,392)	(259,027)
Provision for income taxes	1,171	647	3,113
Net loss	$(16,141)	$(140,039)	$(262,140)
Other comprehensive income (loss):
Unrealized income (loss) on marketable securities	(206)	219	1,186
Foreign currency translation adjustment	169	(230)	(96)
Total other comprehensive income (loss)	(37)	(11)	1,090
Comprehensive loss	$(16,178)	$(140,050)	$(261,050)
Per share information:
Net loss per share, basic and diluted	$(0.13)	$(1.16)	$(3.78)
Weighted-average shares used in computing net loss per share, basic and diluted	127,234	120,958	69,305

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.